Global Alternative Splicing Defects in Human Breast Cancer Cells

被引:6
|
作者
Oh, Jagyeong [1 ]
Pradella, Davide [2 ]
Kim, Yoonseong [1 ]
Shao, Changwei [3 ]
Li, Hairi [3 ]
Choi, Namjeong [1 ]
Ha, Jiyeon [1 ]
Di Matteo, Anna [2 ]
Fu, Xiang-Dong [3 ]
Zheng, Xuexiu [1 ]
Ghigna, Claudia [2 ]
Shen, Haihong [1 ]
机构
[1] Gwangju Inst Sci & Technol, Sch Life Sci, Gwangju 500712, South Korea
[2] CNR, Inst Mol Genet Luigi Luca Cavalli Sforza, Via Abbiategrasso 207, I-27100 Pavia, Italy
[3] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA
基金
新加坡国家研究基金会;
关键词
alternative splicing; breast cancer; exon skipping; intrinsically disordered regions; INTRINSICALLY DISORDERED REGIONS; MECHANISMS; MUTATIONS; LINE; CLASSIFICATION; ASSOCIATION; EXPRESSION; THERAPY; REVEALS;
D O I
10.3390/cancers13123071
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Aberrant alternative splicing (AS) regulation plays a pivotal role in breast cancer development, progression, and resistance to therapeutical interventions. Indeed, cancer cells can adapt their own transcriptome by changing different AS programs, thus generating cancer-specific AS isoforms involved in every hallmark of cancer. Here, we investigated global AS errors occurring in human breast cancer cells by using RNA-mediated oligonucleotide annealing, selection, and ligation coupled with next-generation sequencing. Our results identified several dysregulated AS events potentially relevant for breast cancer-related biological processes and that provide a better comprehension of the molecular mechanisms that orchestrate the malignant transformation. Breast cancer is the most frequently occurred cancer type and the second cause of death in women worldwide. Alternative splicing (AS) is the process that generates more than one mRNA isoform from a single gene, and it plays a major role in expanding the human protein diversity. Aberrant AS contributes to breast cancer metastasis and resistance to chemotherapeutic interventions. Therefore, identifying cancer-specific isoforms is the prerequisite for therapeutic interventions intended to correct aberrantly expressed AS events. Here, we performed RNA-mediated oligonucleotide annealing, selection, and ligation coupled with next-generation sequencing (RASL-seq) in breast cancer cells, to identify global breast cancer-specific AS defects. By RT-PCR validation, we demonstrate the high accuracy of RASL-seq results. In addition, we analyzed identified AS events using the Cancer Genome Atlas (TCGA) database in a large number of non-pathological and breast tumor specimens and validated them in normal and breast cancer samples. Interestingly, aberrantly regulated AS cassette exons in cancer tissues do not encode for known functional domains but instead encode for amino acids constituting regions of intrinsically disordered protein portions characterized by high flexibility and prone to be subjected to post-translational modifications. Collectively, our results reveal novel AS errors occurring in human breast cancer, potentially affecting breast cancer-related biological processes.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing
    Shah, Kalpit
    Gagliano, Teresa
    Garland, Lisa
    O'Hanlon, Timothy
    Bortolotti, Daria
    Gentili, Valentina
    Rizzo, Roberta
    Giamas, Georgios
    Dean, Michael
    ONCOGENE, 2020, 39 (39) : 6172 - 6189
  • [32] HMGA1a induces alternative splicing of estrogen receptor alpha in MCF-7 human breast cancer cells
    Ohe, Kenji
    Miyajima, Shinsuke
    Abe, Ichiro
    Tanaka, Tomoko
    Hamaguchi, Yuriko
    Harada, Yoshihiro
    Horita, Yuta
    Beppu, Yuki
    Ito, Fumiaki
    Yamasaki, Takafumi
    Terai, Hiroki
    Mori, Masayoshi
    Murata, Yusuke
    Tanabe, Makito
    Ashida, Kenji
    Kobayashi, Kunihisa
    Enjoji, Munechika
    Yanase, Toshihiko
    Harada, Nobuhiro
    Utsumi, Toshiaki
    Mayeda, Akila
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2018, 182 : 21 - 26
  • [33] Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics
    Urbanski, Laura M.
    Leclair, Nathan
    Anczukow, Olga
    WILEY INTERDISCIPLINARY REVIEWS-RNA, 2018, 9 (04)
  • [34] Alternative splicing: global insights
    Hallegger, Martina
    Llorian, Miriam
    Smith, Christopher W. J.
    FEBS JOURNAL, 2010, 277 (04) : 856 - 866
  • [35] The Estrogen Receptor α Signaling Pathway Controls Alternative Splicing in the Absence of Ligands in Breast Cancer Cells
    Elhasnaoui, Jamal
    Ferrero, Giulio
    Miano, Valentina
    Cutrupi, Santina
    De Bortoli, Michele
    CANCERS, 2021, 13 (24)
  • [36] Role of SRPK1-modulated Alternative Splicing in Cisplatin Resistance in Breast Cancer Cells
    Wang, Cheng
    Zhou, Zhihong
    Hu, Qidong
    CANCER SCIENCE, 2018, 109 : 560 - 560
  • [37] Relationship between nucleosome positioning and progesterone-induced alternative splicing in breast cancer cells
    Iannone, Camilla
    Pohl, Andy
    Papasaikas, Panagiotis
    Soronellas, Daniel
    Vicent, Guillermo P.
    Beato, Miguel
    Valcarcel, Juan
    RNA, 2015, 21 (03) : 360 - 374
  • [38] SRSF1-Regulated Alternative Splicing in Breast Cancer
    Anczukow, Olga
    Akerman, Martin
    Clery, Antoine
    Wu, Jie
    Shen, Chen
    Shirole, Nitin H.
    Raimer, Amanda
    Sun, Shuying
    Jensen, Mads A.
    Hua, Yimin
    Allain, Frederic H. -T.
    Krainer, Adrian R.
    MOLECULAR CELL, 2015, 60 (01) : 105 - 117
  • [39] Characterization of alternative splicing events and prognostic signatures in breast cancer
    Pihua Han
    Jingjun Zhu
    Guang Feng
    Zizhang Wang
    Yanni Ding
    BMC Cancer, 21
  • [40] Overexpression and alternative splicing of NF-YA in breast cancer
    Dolfini, Diletta
    Andrioletti, Valentina
    Mantovani, Roberto
    SCIENTIFIC REPORTS, 2019, 9 (1)